{"entity":{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","aka":[],"tldr":"Heidelberg is Germany's cancer research capital, home to the DKFZ (largest cancer research institute in Germany) and the NCT, and the birthplace of FAPI PET and the brain tumour methylation classifier.","summary":"Heidelberg University Hospital, with the National Center for Tumor Diseases and the German Cancer Research Center (DKFZ), is Germany's cancer research capital and ranks eighteenth in the Newsweek/Statista oncology list. Its record includes the FAPI PET tracers from Haberkorn, Giesel and Kratochwil, the first-in-human actinium-225 PSMA therapy, the Heidelberg Ion-Beam Therapy Center for carbon ions, the DKFZ brain tumour methylation classifier from Pfister and von Deimling, and the MASTER precision oncology programme, with Stefan Fröhling among its leaders. Nuclide links it to FAP and PSMA as targets, to SOFIE Biosciences, to the first vaccine trial against shared neoantigens of mismatch-repair-deficient cancers, and to ideas for a university cyclotron network and core-funded radiotherapy trials. Turning tracers into approved therapies at scale is the open problem. The DKFZ has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.nct-heidelberg.de"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":["ac-225"],"indications":[],"sections":[],"technologies":["fapi-pet","targeted-alpha-therapy"],"targets":["fap","psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["clemens-kratochwil","frederik-giesel","uwe-haberkorn"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Heidelberg","country":"DE","lat":49.417,"lng":8.67,"institutionType":"cancer-center","website":"https://www.nct-heidelberg.de","newsweekOncology2026":18,"university":"Heidelberg University","programs":["FAPI PET","Alpha PSMA therapy","Carbon-ion therapy","CNS methylation classifier","DKFZ basic research"]},"route":"/institutions/heidelberg-nct/","neighbours":{"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"}],"technology":[{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"person":[{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","route":"/people/clemens-kratochwil/"},{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/"},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/"}],"indication":[{"id":"glioblastoma","kind":"indication","name":"Glioma & glioblastoma","route":"/indications/glioblastoma/"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"}],"company":[{"id":"sofie-biosciences","kind":"company","name":"SOFIE Biosciences","route":"/companies/sofie-biosciences/"}],"institution":[{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/"},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/"},{"id":"uk-duesseldorf","kind":"institution","name":"University Hospital Düsseldorf / CIO Düsseldorf","route":"/institutions/uk-duesseldorf/"}],"idea":[{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/"}]}}